Our investments in Alzheimer’s disease drug discovery research are getting tangible results. Specifically, ADDF supported research that:
- Screened millions of compounds, the chemicals that can become drugs
- Developed promising new chemicals and new classes of treatments
- Resulted in numerous patents filed and licenses for new drugs
- Advanced novel chemicals to human testing
- Invested more than $9.6 million to 42 biotechnology companies
- Invested more than $45 million in new drug discovery programs worldwide, which have received follow-on commitments of more than $2 billion